An Open-label, randomised, controlled, multi-centre study of the immunogenicity and safety of a booster dose of two different Hepatitis B vaccines to explore the anamnestic immune response in healthy 4 to 7 year-old children previously vaccinated at about 3, 5 and 11 to 13 months of age with either HEXAVAC or INFANRIX-HEXA Immunogenicity To describe in subjects vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre &#...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older - To demonstrate that REPEVAX administered concomitantly with VAXIGRIP in subjects 60 years of age and older is at least as immunogenic as REPEVAX administered alone and - To demonstrate that VAXIGRIP...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age Two co-primary objectives are: To demonstrate that ZOSTAVAX® administered by intramuscular (IM) route is non-inferior to ZOSTAVAX® administered by subcutaneous (SC) route in terms of 4-week post-vacci...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyelitis vaccine (REVAXIS®) in subjects of 40 years of age or older without a previous diphtheria and tetanus-containing booster within the last 20 years To demonstrate that 3 doses of a vaccine containing Td-IPV valences administered in a 0, 1 and 6-month schedule induce an acceptable immune response in terms of seroprotection rates (SPR) against diph...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all current process polysaccharides To compare the post-vaccination geometric mean titres (GMTs) of antibody to pneumococcal serotypes 3 and 8 in recipients of PNEUMOVAX®II formulated with all new process polysaccharides to the same ant...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III randomized, double-blind, active-comparator controlled clinical trial to study the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2, 4, and 11 to 12 months To evaluate the immunogenicity of PR5I when given at 2, 4, and 11 to 12 months of age.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old To demonstrate that the administration of GARDASIL®9 in 27- to 45 year old women induces non inferior geometric mean titres (GMTs) for serum anti-HPV 16, 18, 31, 33, 45, 52, and 58 compared with 16- t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

study of the immunogenicity and safety of a decoy dose of HBVAXPRO®, in healthy children vaccinated 10 years ago with 3 doses of HEXAVAC® or INFANRIX®-HEXA. studio sull'immunogenicità e sulla sicurezza della dose di richiamo con HBVAXPRO®, in bambini sani vaccinati 10 prima con 3 dosi di HEXAVAC® o INFANRIX®-HEXA *To describe, in subjects vaccinated with 3 doses of HEXAVAC® as infants, the percentage of subjects with an anti-HBs concentration ≥10 mIU/mL one month after a challenge dose of HBVAXPRO® given at le...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infants To demonstrate that RotaTeq® can be administered concomitantly with MCC vaccine to healthy infants without impairing the antibody seroprotection rate to meningococcal Group C serotype as measured by s...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A new vaccine for babies which adds protection against hepatitis B To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT and MCC-CRM) to healthy infants at 3 and 4 months of age in term of antibody seroprotection rate (SPR) to MCC.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune